Annual Report 2003

Chairman's message

Financial highlights

Management

Product review

Research pipeline

Selected licensing agreements

Financial section

Board of Directors

Corporate information

Merck's commitment:
novel medicines that make
a difference

click photos

Product review¹


Arcoxia™ (etoricoxib)	Osteoarthritis Chronic low back pain Rheumatoid arthritis (adult) Dysmenorrhea (menstrual pain) Acute pain Acute gouty arthritis

Cancidas® (caspofungin acetate)	Treatment of invasive aspergillosis in patients who did not respond to or were intolerant of other antifungal therapies Candida infections: intra-abdominal abscesses, peritonitis (infections within the lining of the abdominal cavity), pleural space infections (infections within the lining of the lung) Candidemia (bloodstream infection) Esophageal candidiasis

Comvax® (Haemophilus b conjugate and hepatitis B [recombinant] vaccine)	Haemophilus influenzae type b disease and hepatitis B disease

Cosopt® (dorzolamide hydrochloride and timolol maleate)	Lower intraocular pressure

Cozaar® (losartan potassium)	High blood pressure Reduction in progression of renal disease in patients with Type II diabetes, hypertension and nephropathy Reduction of stroke risk in patients with hypertension and left ventricular hypertrophy²

Crixivan® (indinavir sulfate)	HIV infection

Emend® (aprepitant)	Prevention of chemotherapy-induced nausea and vomiting

Fosamax® (alendronate sodium)	Treatment and prevention of postmenopausal osteoporosis Reduction of osteoporotic fracture risk in postmenopausal women Treatment of male osteoporosis to increase bone mass Treatment of glucocorticoid-induced osteoporosis Paget's disease of the bone

Hyzaar® (losartan potassium and hydrochlorothiazide)	High blood pressure

Invanz® (ertapenem sodium)	Treatment of many aerobic and anaerobic bacteria, particularly community acquired, such as complicated intra-abdominal and complicated skin and skin structure infections

Maxalt® (rizatriptan benzoate)	Acute migraine

Pepcid AC® (famotidine)³	Heartburn

Primaxin® (imipenem and cilastatin)	Antibiotic

Propecia® (finasteride)	Treatment of male pattern hair loss

Proscar® (finasteride)	Treatment of symptomatic benign prostate enlargement

Singulair® (montelukast sodium)	Chronic asthma-adults and children as young as 12 months old Seasonal allergic rhinitis-adults and children as young as age 2

Stocrin® (efavirenz)⁴	HIV infection

Timoptic-XE® (timolol maleate ophthalmic gel forming solution)	Lower intraocular pressure

Trusopt® (dorzolamide hydrochloride)	Lower intraocular pressure

Vaqta® (hepatitis A vaccine inactivated)	Hepatitis A

Varivax® (varicella virus vaccine live [Oka/Merck strain])	Chickenpox

Vioxx® (rofecoxib)	Osteoarthritis Rheumatoid arthritis (adult) Acute pain Dysmenorrhea (menstrual pain)

Zetia® (ezetimibe)⁵	Elevated cholesterol levels

Zocor® (simvastatin)	Elevated total cholesterol levels Raise HDL cholesterol Associated total/coronary mortality⁶ Reduce triglycerides Lower LDL cholesterol Reduce stroke risk⁶


¹	This list excludes a number of older Company products introduced before 1990.
²	There is evidence that this benefit does not apply to black patients.
³	Marketed by Johnson & Johnson · Merck Consumer Pharmaceuticals Co.
⁴	Efavirenz is marketed by Bristol-Myers Squibb as Sustiva in the U.S., Canada and certain European countries, and by Merck in the rest of the world as Stocrin.
⁵	Ezetimibe is marketed through a partnership with Schering-Plough Corporation.
⁶	In patients with coronary heart disease or diabetes.

Back to top